Digital Pathology Market, by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 884.4 Million in 2023 and is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing number of cancer cases worldwide is expected to boost the market growth over forecast period. For instance, according to World Cancer Research Fund International, there were 18,094,716 new cases of cancer in 2020 worldwide. Among these, 7.8% were prostate cancer, 12.5% were breast cancer, and 10.7% were colorectal cancer, among other cancer types.
Digital Pathology Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019," or COVID-19. This virus spreads quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
The COVID-19 had a positive impact on the global digital pathology market, as many pharmaceutical and medical device companies were focusing on developing image analysis software and slide scanners for digital pathologies. For instance, in September 2020, according to the data published by the National Centers for Biotechnology Information, due to the strict federal regulations of the U.S. Food and Drug Administration (FDA) and the Clinical Laboratory Improvement Amendments (CLIA) from the Centers for Medicare & Medicaid Services, the U.S. lagged behind most developed nations in terms of the adoption of digital pathology prior to the COVID-19 pandemic. The U.S. Food and Drug Administration relaxed some of its requirements to approve and validate digital pathology-related technology to meet the pandemic response's needs. Similarly, the Centers for Medicare & Medicaid Services waived restrictive Clinical Laboratory Improvement Amendments (CLIA) rules that allowed pathologists to use digital pathology platforms from home during the COVID-19 pandemic.
Digital Pathology Market: Key Developments
In November 2022, Nucleai, a software company, expanded its spatial biology platform by introduction of a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of multiplex immunofluorescence (mIF) data for drug discovery and development.
In December 2022, Deciphex, an Ireland-based company that provides pathology software and services, launched Digital Research Pathology Platform named Patholytix 3.0. The new platform is intended to overcome the limitations of Laboratory Information Management System (LIMS) software, which enables users to efficiently manage samples and associated data. It intends to change the tools accessible to research pathologists internationally. With the introduction of Patholytix 3.0, users may now evaluate and score non-clinical investigations on a single platform for the first time, leading to quicker and less error-prone pathology evaluations. In contrast to the outdated Viewer + LIMS system procedures, discoveries can now be geo-located to exactly where they are in the slide or displayed as text in the grid. As a result, there is no longer a chance for human error while entering data or a requirement to manually match a slide with its findings.
In December 2022, FUJIFILM Corporation, a photography company, announced that it had signed an agreement to acquire digital pathology technology assets, as part of which it would buy the digital pathology technology assets of Inspirata, a provider of cancer diagnostics solution. As part of the acquisition, the digital pathology offerings, customers, and employees of Inspirata will integrate with FUJIFILM Corporation.
On January 18, 2023, Proscia Inc., a software company, announced the adoption of its Concentriq Dx, a digital pathology platform by the Netherlands Cancer Institute (NKI), a cancer center in Netherlands, Europe. To grow its digital pathology practice, NKI is switching to Concentriq Dx, establishing the groundwork for its pathologists to provide tailored diagnoses that will better guide treatment choices.
Browse 44 Market Data Tables and 38 Figures spread through 240 Pages and in-depth TOC on “Digital Pathology Market”- Forecast to 2030, by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/digital-pathology-market-379
Key Takeaways of the Digital Pathology Market:
- The global high-intensity focused ultrasound (HIFU) market is expected to exhibit a CAGR of 12.2% during the forecast period. Increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, according to Cancer Research U.K., a cancer research organization in the U.K., in 2021, 1 in 2 people in the U.K. will be diagnosed with cancer in their lifetime, where 387,820 cases of cancer were diagnosed in 2019, of which 200,386 were in men and 187,434 were in women.
- Among product type, Image Analysis Software segment is estimated to hold a dominant position in the global high-intensity focused ultrasound (HIFU) market over the forecast period, owing to increasing product launches by market players. For instance, on August 23, 2021, Xybion Digital Inc., a software-as-a-service company, announced the launch of Pristima XD Digital Pathology. Xybion’s Digital Pathology software provides improved lab throughput while allowing pathologists to streamline their peer-review workflows.
- Among regions, North America is expected to be the most dominant region in the Digital Pathology Market, owing to increase in the number of autoimmune diseases such as Graves disease. For instance, in December 2022, according to the data published by the National Center for Biotechnology Information, it was found that in the year 2022, the incidence of Graves' disease had increased by 9.6% as compared to the year 2021. Furthermore, in December 2022, according to the same source, it was also estimated that in the year 2022, one in every 200 people in the North America region suffered from the Graves' disease.
- Major players operating in the Digital Pathology Market include Leica Biosystems Nussloch GmbH, Olympus Corporation, Hoffmann-La Roche Ltd., Merck KGaA, GE Healthcare, Mikroscan Technologies, Inc., Koninklijke Philips N.V., Sectra AB, Propath UK Limited, Inspirata, Inc., Hamamatsu Photonics, Inc., OracleBio Limited, MD Biosciences, Aiforia, Xybion Digital Inc.
